National•International Bureau•16 Nov 2026, 09:55 PM PKT•2 min read•1,807 Reads
Lgalmi: US FDA approves at-home use of agitation drug
Lgalmi: US FDA approves at-home use of agitation drug. National News Pakistan correspondents report that administrative desks and on-ground observers are closely monitoring developments across Pakistan.
60-Second Editorial Quick Summaryخلاصہ
Verified facts & intelligence briefed by National News Press Bureau.
Lgalmi: US FDA approves at-home use of agitation drug — reported as a key national national development in Pakistan.
Official statements and regulatory updates are actively monitored by the NNP Central Wire.
NNP Central Editorial Research Desk
#Pakistan National Bureau#National Desk

Photo: National News Pakistan Bureau
INTERNATIONAL BUREAU —
Key Takeaways & Executive Analysis
- Promotional image shared by Bioxcel The US Food and Drug Administration on Monday approved at-home use of BioXcel Therapeutics’ drug, Igalmi, for agitation associated with schizophrenia or bipolar disorder.
- According to field observations and verified reporting compiled by the International bureau desk: The company last month completed the sale of nearly all its assets, including Igalmi, to a unit of Teva Pharmaceuticals.
- The approval expands Igalmi’s use to outpatient settings without supervision of a healthcare provider, where there are no FDA-approved options available, Teva said.
Verified National Coverage: Published by National News Press (International Bureau). Fact-checked and verified.
Verified Editorial DeskAudience Reviews & Discussion
Share your perspective, rate coverage accuracy, and engage with verified readers across Pakistan.
Rate This Story
